Group 1 - Eikon Therapeutics raised $381.2 million in its IPO by issuing approximately 21.2 million shares at a price of $18 per share, which is at the upper limit of its target range of $16 to $18 [1] - The IPO market in the U.S. is showing signs of recovery in 2026, following a slowdown due to a government shutdown in October last year that delayed many companies' listing plans [1] - The company was founded in 2019 by Nobel Prize winners Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian, and is currently developing multiple experimental cancer therapies [1] Group 2 - Eikon Therapeutics' stock will begin trading on Nasdaq under the ticker symbol "EIKN" [2] - The underwriters for the IPO include major financial institutions such as JPMorgan, Morgan Stanley, Bank of America Securities, Cantor, and Mizuho Securities [2] Group 3 - The company's lead candidate drug, EIK1001, is undergoing a late-stage clinical trial in combination with Merck's Keytruda for skin cancer, with interim analysis data expected to be released in the second half of 2026 [1]
生物医药公司Eikon Therapeutics(EIKN.US)IPO定价18美元募资3.812亿 今晚登陆纳斯达克